N10: Reduced Therapy for High-Risk Neuroblastoma
Status: Recruiting
Location: See location...
Intervention Type: Biological, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 19
Healthy Volunteers: f
View:
• Diagnosis of NB as defined by histopathology, BM metastases plus high urine catecholamine levels, or positivity in MIBG scan.
• HR-NB, defined as MYCN-amplified stage L2/M/MS at any age and stage M in patients \>18 months old.
• No more than one prior cycle of HR-NB chemotherapy
• Age \<19 years.
• Signed informed consent indicating awareness of the investigational nature of this treatment.
Locations
United States
New York
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Contact Information
Primary
Brian Kushner, MD
kushnerb@MSKCC.ORG
8336755491
Backup
Fiorella Iglasias Cardenas, MD, MS
iglesiaf@mskcc.org
Time Frame
Start Date: 2024-07-22
Estimated Completion Date: 2029-07-22
Participants
Target number of participants: 45
Treatments
Experimental: Participants with Neuroblastoma
Participants will receive 4 cycles of induction chemotherapy followed by a response-based intervention.
Related Therapeutic Areas
Sponsors
Leads: Memorial Sloan Kettering Cancer Center